Guerbet sells its pharmaceutical site in Montreal to MedXL

Date Closed

July 14, 2020

Lead Office


On July 15, 2020, Guerbet sold its pharmaceutical site in Montreal to MedXL, a specialist in medical devices and sterile pre-filled syringes.

The Montreal industrial facility specializes on the one hand in filling and finishing of contrast media and on the other in the large-series manufacture of syringes pre-filled with sterile solutions for third parties, which is not a core business for Guerbet. Guerbet will gradually transfer its contrast agent production, carried out previously in Montreal, to its pharmaceutical sites in France and the United States. This sale is a part of Guerbet’s plans to optimize its industrial network. The operation will make Guerbet more competitive by improving capacity utilization at its other manufacturing sites.

Guerbet, based in France, is a leader in medical imaging worldwide, offering a wide range of pharmaceutical products, medical devices, digital and AI solutions for diagnostic and interventional imaging, to improve the diagnosis and treatment of patients.

McCarthy Tétrault LLP advised Guerbet with a team led by Patrick M. Shea that included Vincent Laurin, Camille Marceau and Marieve St-Pierre (Corporate and M&A), Véronique Wattiez Larose (IP), Marie-Soleil Landry , Christian Meighen and Quentin Lageix (Tax), Dominic Thérien and Julien Beaulieu (Competition), Eve Tessier (Financial Services) and Philippe Côté (Real Estate).